|
Delaware
|
|
04-3158289
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
21 Erie Street
Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Large accelerated filer
o
|
|
Accelerated filer
o
|
|
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
x
|
(Do not check if a smaller reporting company)
|
|
|
|
|
|
Page
|
|
|
|
Item
|
|
|
|
||
|
||
|
||
|
||
|
||
|
|
|
|
|
|
Item
|
|
|
|
|
|
|
|
September 30,
2015 |
|
December 31,
2014 |
|
||||
Assets
|
|
|
|
|
|
||||
Current Assets:
|
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
17,894
|
|
|
$
|
20,046
|
|
|
Accounts receivable
|
|
276
|
|
|
45
|
|
|
||
Due from related parties
|
|
147
|
|
|
112
|
|
|
||
Unbilled receivables
|
|
288
|
|
|
420
|
|
|
||
Inventory
|
|
375
|
|
|
586
|
|
|
||
Prepaid expenses and other current assets
|
|
1,443
|
|
|
756
|
|
|
||
Total current assets
|
|
20,423
|
|
|
21,965
|
|
|
||
Restricted cash
|
|
619
|
|
|
619
|
|
|
||
Property and equipment, net
|
|
908
|
|
|
456
|
|
|
||
Other assets
|
|
170
|
|
|
95
|
|
|
||
Total assets
|
|
$
|
22,120
|
|
|
$
|
23,135
|
|
|
|
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity
|
|
|
|
|
|
||||
Current Liabilities:
|
|
|
|
|
|
||||
Accounts payable
|
|
$
|
448
|
|
|
$
|
333
|
|
|
Accrued expenses
|
|
3,590
|
|
|
3,709
|
|
|
||
Deferred revenue
|
|
154
|
|
|
147
|
|
|
||
Total current liabilities
|
|
4,192
|
|
|
4,189
|
|
|
||
Other long-term liabilities
|
|
150
|
|
|
150
|
|
|
||
Total liabilities
|
|
4,342
|
|
|
4,339
|
|
|
||
|
|
|
|
|
|
||||
Commitments and contingencies (Note 9)
|
|
|
|
|
|
||||
|
|
|
|
|
|
||||
Stockholders’ Equity:
|
|
|
|
|
|
||||
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding
|
|
—
|
|
|
—
|
|
|
||
Common stock ($0.01 par value per share); 250,000,000 shares authorized at September 30, 2015 and December 31, 2014; 26,981,214 and 22,530,322 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively
|
|
270
|
|
|
225
|
|
|
||
Additional paid-in capital
|
|
337,416
|
|
|
320,707
|
|
|
||
Accumulated other comprehensive loss
|
|
(72
|
)
|
|
(64
|
)
|
|
||
Accumulated deficit
|
|
(319,836
|
)
|
|
(302,072
|
)
|
|
||
Total stockholders’ equity
|
|
17,778
|
|
|
18,796
|
|
|
||
Total liabilities and stockholders’ equity
|
|
$
|
22,120
|
|
|
$
|
23,135
|
|
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Revenue:
|
|
|
|
|
|
|
|
|
||||||||
Product revenue
|
|
$
|
209
|
|
|
$
|
115
|
|
|
$
|
394
|
|
|
$
|
428
|
|
Grant revenue
|
|
327
|
|
|
390
|
|
|
1,249
|
|
|
1,301
|
|
||||
License fee and royalty revenue
|
|
173
|
|
|
127
|
|
|
455
|
|
|
215
|
|
||||
Total revenue
|
|
709
|
|
|
632
|
|
|
2,098
|
|
|
1,944
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Costs and expenses:
|
|
|
|
|
|
|
|
|
||||||||
Cost of product revenue
|
|
347
|
|
|
786
|
|
|
521
|
|
|
1,372
|
|
||||
Research and development
|
|
4,088
|
|
|
4,088
|
|
|
12,332
|
|
|
13,280
|
|
||||
Selling, general, and administrative
|
|
2,156
|
|
|
2,472
|
|
|
7,086
|
|
|
8,269
|
|
||||
Total costs and expenses
|
|
6,591
|
|
|
7,346
|
|
|
19,939
|
|
|
22,921
|
|
||||
Loss from continuing operations
|
|
(5,882
|
)
|
|
(6,714
|
)
|
|
(17,841
|
)
|
|
(20,977
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Other income (expense):
|
|
|
|
|
|
|
|
|
||||||||
Interest income, net
|
|
1
|
|
|
4
|
|
|
3
|
|
|
6
|
|
||||
Other income (expense), net
|
|
33
|
|
|
2
|
|
|
74
|
|
|
10
|
|
||||
Total other income (expense), net
|
|
34
|
|
|
6
|
|
|
77
|
|
|
16
|
|
||||
Net loss from continuing operations
|
|
(5,848
|
)
|
|
(6,708
|
)
|
|
(17,764
|
)
|
|
(20,961
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Discontinued operations:
|
|
|
|
|
|
|
|
|
||||||||
Loss from discontinued operations
|
|
—
|
|
|
(294
|
)
|
|
—
|
|
|
(1,430
|
)
|
||||
Loss from write down of assets held for sale
|
|
—
|
|
|
(891
|
)
|
|
—
|
|
|
(891
|
)
|
||||
Total loss from discontinued operations
|
|
—
|
|
|
(1,185
|
)
|
|
—
|
|
|
(2,321
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Net loss
|
|
$
|
(5,848
|
)
|
|
$
|
(7,893
|
)
|
|
$
|
(17,764
|
)
|
|
$
|
(23,282
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
Basic and diluted net loss per share:
|
|
|
|
|
|
|
|
|
||||||||
Net loss from continuing operations
|
|
$
|
(0.22
|
)
|
|
$
|
(0.71
|
)
|
|
$
|
(0.73
|
)
|
|
$
|
(2.99
|
)
|
Net loss from discontinued operations
|
|
—
|
|
|
(0.13
|
)
|
|
—
|
|
|
(0.33
|
)
|
||||
Net loss per share
|
|
$
|
(0.22
|
)
|
|
$
|
(0.84
|
)
|
|
$
|
(0.73
|
)
|
|
$
|
(3.32
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
Number of shares used in per share calculations:
|
|
|
|
|
|
|
|
|
||||||||
Basic & Diluted
|
|
26,979,598
|
|
|
9,381,316
|
|
|
24,234,043
|
|
|
7,017,749
|
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Net loss:
|
|
$
|
(5,848
|
)
|
|
$
|
(7,893
|
)
|
|
$
|
(17,764
|
)
|
|
$
|
(23,282
|
)
|
Other comprehensive loss
|
|
|
|
|
|
|
|
|
||||||||
Change in unrealized loss on investments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
||||
Change in foreign currency translation adjustment
|
|
(3
|
)
|
|
(109
|
)
|
|
(7
|
)
|
|
(140
|
)
|
||||
Total other comprehensive loss
|
|
(3
|
)
|
|
(109
|
)
|
|
(7
|
)
|
|
(141
|
)
|
||||
Comprehensive loss
|
|
$
|
(5,851
|
)
|
|
$
|
(8,002
|
)
|
|
$
|
(17,771
|
)
|
|
$
|
(23,423
|
)
|
|
|
Nine Months Ended September 30,
|
||||||
|
|
2015
|
|
2014
|
||||
Cash flows from operating activities
|
|
|
|
|
||||
Net loss
|
|
$
|
(17,764
|
)
|
|
$
|
(23,282
|
)
|
Less:
|
|
|
|
|
||||
Loss from discontinued operation
|
|
—
|
|
|
(2,321
|
)
|
||
Loss from continuing operations
|
|
(17,764
|
)
|
|
(20,961
|
)
|
||
Adjustments to reconcile net loss to cash used in operating activities:
|
|
|
|
|
||||
Depreciation
|
|
167
|
|
|
430
|
|
||
Charge for 401(k) company common stock match
|
|
291
|
|
|
332
|
|
||
Stock-based compensation
|
|
1,483
|
|
|
1,912
|
|
||
Inventory impairment
|
|
202
|
|
|
886
|
|
||
Gain on sale of property and equipment
|
|
(33
|
)
|
|
—
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
||||
Accounts receivables
|
|
(231
|
)
|
|
769
|
|
||
Due from related party
|
|
(35
|
)
|
|
(49
|
)
|
||
Unbilled receivables
|
|
132
|
|
|
34
|
|
||
Inventory
|
|
9
|
|
|
191
|
|
||
Prepaid expenses and other assets
|
|
(687
|
)
|
|
254
|
|
||
Accounts payable
|
|
48
|
|
|
(211
|
)
|
||
Accrued expenses
|
|
18
|
|
|
(1,355
|
)
|
||
Deferred rent and other long-term liabilities
|
|
—
|
|
|
(50
|
)
|
||
Deferred revenue
|
|
7
|
|
|
(364
|
)
|
||
Net cash used by continuing operations for operating activities
|
|
(16,393
|
)
|
|
(18,182
|
)
|
||
Net cash used by discontinued operations for operating activities
|
|
—
|
|
|
(460
|
)
|
||
Net cash used in operating activities
|
|
(16,393
|
)
|
|
(18,642
|
)
|
||
|
|
|
|
|
||||
Cash flows from investing activities
|
|
|
|
|
||||
Purchase of property and equipment
|
|
(498
|
)
|
|
(153
|
)
|
||
Proceeds from sale of equipment
|
|
40
|
|
|
—
|
|
||
Purchase of short-term investments
|
|
—
|
|
|
(1,508
|
)
|
||
Proceeds from the sale and maturity of short-term investments
|
|
—
|
|
|
13,019
|
|
||
Net cash (used by) provided by investing activities
|
|
(458
|
)
|
|
11,358
|
|
||
|
|
|
|
|
||||
Cash flows from financing activities
|
|
|
|
|
||||
Proceeds from options exercised
|
|
—
|
|
|
300
|
|
||
Proceeds from private placement offerings, net of issuance costs
|
|
14,703
|
|
|
24,913
|
|
||
Net cash provided by financing activities
|
|
14,703
|
|
|
25,213
|
|
||
|
|
|
|
|
||||
Effect of exchange rate changes on cash and cash equivalents
|
|
(4
|
)
|
|
(141
|
)
|
||
|
|
|
|
|
||||
Net (decrease) increase in cash and cash equivalents
|
|
(2,152
|
)
|
|
17,788
|
|
||
Cash and cash equivalents at beginning of period
|
|
20,046
|
|
|
7,698
|
|
||
Cash and cash equivalents at end of period
|
|
$
|
17,894
|
|
|
$
|
25,486
|
|
Supplemental disclosure of non-cash information:
|
|
|
|
|
||||
Purchase of property and equipment included in accounts payable and accrued expenses
|
|
$
|
128
|
|
|
$
|
—
|
|
Offering costs included in accrued expenses
|
|
$
|
75
|
|
|
$
|
—
|
|
Restricted stock units issued to settle incentive compensation obligation
|
|
$
|
305
|
|
|
$
|
—
|
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
|
||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
|
||||
Options
|
|
928,090
|
|
|
1,169,058
|
|
|
956,181
|
|
|
1,217,890
|
|
|
Convertible Series B Preferred Stock
|
|
—
|
|
|
8,333,333
|
|
|
—
|
|
|
8,333,333
|
|
|
Restricted stock units
|
|
1,198,743
|
|
|
100,000
|
|
|
830,530
|
|
|
99,634
|
|
|
Warrants
|
|
3,933,000
|
|
|
—
|
|
|
1,541,505
|
|
|
—
|
|
|
Total
|
|
6,059,833
|
|
|
9,602,391
|
|
|
3,328,216
|
|
|
9,650,857
|
|
|
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
Raw materials
|
|
$
|
38
|
|
|
$
|
2
|
|
Work in Process
|
|
6
|
|
|
—
|
|
||
Finished goods
|
|
331
|
|
|
584
|
|
||
Total inventory
|
|
$
|
375
|
|
|
$
|
586
|
|
|
|
Fair value measurements at reporting date using
|
|
|
||||||||||||
|
|
Quoted prices in active markets for identical
assets
|
|
Significant other
observable inputs
|
|
Significant
unobservable inputs
|
|
Balance as of
|
||||||||
Description
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
September 30, 2015
|
||||||||
Cash equivalents:
|
|
|
|
|
|
|
|
|
||||||||
Money market funds
|
|
$
|
15,511
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15,511
|
|
Total
|
|
$
|
15,511
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15,511
|
|
|
|
Fair value measurements at reporting date using
|
|
|
||||||||||||
|
|
Quoted prices in active markets for identical
assets
|
|
Significant other
observable inputs
|
|
Significant
unobservable inputs
|
|
Balance as of
|
||||||||
Description
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
December 31, 2014
|
||||||||
Cash equivalents:
|
|
|
|
|
|
|
|
|
||||||||
Money market funds
|
|
$
|
19,011
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
19,011
|
|
Total
|
|
$
|
19,011
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
19,011
|
|
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
Employee compensation and benefits
|
|
$
|
2,026
|
|
|
$
|
2,621
|
|
Professional services
|
|
724
|
|
|
564
|
|
||
Pilot manufacturing
|
|
303
|
|
|
77
|
|
||
Other
|
|
537
|
|
|
447
|
|
||
Total accrued expenses
|
|
$
|
3,590
|
|
|
$
|
3,709
|
|
|
|
Number of
Shares
|
|
Weighted Average
Exercise Price
|
|||
Outstanding at December 31, 2014
|
|
1,110,721
|
|
|
$
|
28.22
|
|
Granted
|
|
31,208
|
|
|
3.72
|
|
|
Exercised
|
|
—
|
|
|
—
|
|
|
Forfeited
|
|
(1,677
|
)
|
|
7.88
|
|
|
Expired
|
|
(232,936
|
)
|
|
31.41
|
|
|
Outstanding at September 30, 2015
|
|
907,316
|
|
|
$
|
26.59
|
|
|
|
|
|
|
|||
Options exercisable at September 30, 2015
|
|
594,188
|
|
|
$
|
36.29
|
|
|
|
|
|
|
|||
Weighted average grant date fair value of options granted during the nine months ended September 30, 2015
|
|
|
|
$
|
2.68
|
|
|
Number of RSUs
|
Weighted Average Remaining Contractual Life (years)
|
||
Outstanding at December 31, 2014
|
100,000
|
|
|
|
Awarded
|
1,192,023
|
|
|
|
Released
|
—
|
|
|
|
Forfeited
|
(1,000
|
)
|
|
|
Outstanding at September 30, 2015
|
1,291,023
|
|
1.54
|
|
|
|
|
||
Vested and expected to vest as of September 30, 2015
|
1,122,027
|
|
1.42
|
|
|
|
|
||
Weighted average remaining recognition period
|
2.60
|
|
|
|
Weighted average grant date fair value of RSUs granted during the nine months ended September 30, 2015
|
$
|
3.61
|
|
|
|
|
U.S.
|
|
Canada
|
|
Eliminations
|
|
Total
|
||||||||
Three Months Ended September 30, 2015:
|
|
|
|
|
|
|
|
|
||||||||
Net revenues from unaffiliated customers
|
|
$
|
709
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
709
|
|
Inter-geographic revenues
|
|
—
|
|
|
192
|
|
|
(192
|
)
|
|
—
|
|
||||
Net revenues
|
|
$
|
709
|
|
|
$
|
192
|
|
|
$
|
(192
|
)
|
|
$
|
709
|
|
|
|
|
|
|
|
|
|
|
||||||||
Three Months Ended September 30, 2014:
|
|
|
|
|
|
|
|
|
||||||||
Net revenues from unaffiliated customers
|
|
$
|
600
|
|
|
$
|
32
|
|
|
$
|
—
|
|
|
$
|
632
|
|
Inter-geographic revenues
|
|
—
|
|
|
185
|
|
|
(185
|
)
|
|
—
|
|
||||
Net revenues
|
|
$
|
600
|
|
|
$
|
217
|
|
|
$
|
(185
|
)
|
|
$
|
632
|
|
|
|
|
|
|
|
|
|
|
||||||||
Nine Months Ended September 30, 2015:
|
|
|
|
|
|
|
|
|
||||||||
Net revenues from unaffiliated customers
|
|
$
|
2,097
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
2,098
|
|
Inter-geographic revenues
|
|
—
|
|
|
594
|
|
|
(594
|
)
|
|
—
|
|
||||
Net revenues
|
|
$
|
2,097
|
|
|
$
|
595
|
|
|
$
|
(594
|
)
|
|
$
|
2,098
|
|
|
|
|
|
|
|
|
|
|
||||||||
Nine Months Ended September 30, 2014:
|
|
|
|
|
|
|
|
|
||||||||
Net revenues from unaffiliated customers
|
|
$
|
1,830
|
|
|
$
|
114
|
|
|
$
|
—
|
|
|
$
|
1,944
|
|
Inter-geographic revenues
|
|
—
|
|
|
545
|
|
|
(545
|
)
|
|
—
|
|
||||
Net revenues
|
|
$
|
1,830
|
|
|
$
|
659
|
|
|
$
|
(545
|
)
|
|
$
|
1,944
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
|
Canada
|
|
Eliminations
|
|
Total
|
||||||||
September 30, 2015
|
|
$
|
903
|
|
|
$
|
5
|
|
|
$
|
—
|
|
|
$
|
908
|
|
December 31, 2014
|
|
$
|
441
|
|
|
$
|
15
|
|
|
$
|
—
|
|
|
$
|
456
|
|
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
||||
|
2014
|
2014
|
||||
Total revenue
|
$
|
434
|
|
$
|
1,361
|
|
Costs and expenses:
|
|
|
|
|||
Cost of product revenue
|
413
|
|
405
|
|
||
Research and development
|
15
|
|
242
|
|
||
Selling, general and administrative
|
300
|
|
2,144
|
|
||
Loss from write-down of assets held for sale
|
891
|
|
891
|
|
||
Total costs and expenses
|
1,619
|
|
3,682
|
|
||
Net loss
|
$
|
(1,185
|
)
|
$
|
(2,321
|
)
|
|
Original Charges and Amounts Accrued
|
Adjustments to Charges
|
Amounts Paid through September 30, 2015
|
Amounts Accrued at September 30, 2015
|
||||||||
Employee severance, benefits and related costs
|
$
|
624
|
|
$
|
35
|
|
$
|
(580
|
)
|
$
|
79
|
|
|
$
|
624
|
|
$
|
35
|
|
$
|
(580
|
)
|
$
|
79
|
|
|
|
Funding
Agency
|
|
Total Government Funds
|
|
Total received
through
|
|
Remaining amount
available as of
|
|
Contract/Grant
Expiration
|
||||||
Program Title
|
|
|
|
September 30, 2015
|
|
September 30, 2015
|
|
|||||||||
Production of High Oil, Transgene Free Camelina Sativa Plants through Genome Editing
|
|
Department of Energy
|
|
$
|
1,997
|
|
|
$
|
—
|
|
|
$
|
1,997
|
|
|
September 2017
|
Renewable Enhanced Feedstocks For Advanced Biofuels And Bioproducts ("REFABB")
|
|
Department of Energy
|
|
6,000
|
|
|
5,623
|
|
|
377
|
|
|
February 2016
|
|||
Subcontract from University of California (Los Angeles) project funded by ARPA-E entitled “Plants Engineered to Replace Oil: Energy Plant Design”
|
|
Department of Energy
|
|
819
|
|
|
715
|
|
|
104
|
|
|
September 2015
|
|||
Capacity Building for Commercial-Scale PHB Camelina Development
|
|
National Research Council Canada
|
|
269
|
|
|
269
|
|
|
—
|
|
|
September 2014
|
|||
Subcontract from University of Massachusetts (Amherst) project funded by ARPA-E entitled “Development of a Dedicated High Value Biofuels Crop”
|
|
Department of Energy
|
|
663
|
|
|
643
|
|
|
20
|
|
|
December 2015
|
|||
Development of a Sustainable Value Added Fish Feed Using PHB Producing Camelina
|
|
National Research Council Canada
|
|
96
|
|
|
83
|
|
|
—
|
|
|
January 2015
|
|||
Total
|
|
|
|
$
|
9,844
|
|
|
$
|
7,333
|
|
|
$
|
2,498
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
||||||||
|
|
2015
|
|
2014
|
|
Change
|
||||||
Product revenue
|
|
$
|
209
|
|
|
$
|
115
|
|
|
$
|
94
|
|
Grant revenue
|
|
327
|
|
|
390
|
|
|
(63
|
)
|
|||
License fee and royalty revenue
|
|
173
|
|
|
127
|
|
|
46
|
|
|||
Total revenue
|
|
$
|
709
|
|
|
$
|
632
|
|
|
$
|
77
|
|
|
|
Three Months Ended
September 30,
|
|
|
||||||||
|
|
2015
|
|
2014
|
|
Change
|
||||||
Cost of product revenue
|
|
$
|
347
|
|
|
$
|
786
|
|
|
$
|
(439
|
)
|
Research and development expenses
|
|
4,088
|
|
|
4,088
|
|
|
—
|
|
|||
Selling, general, and administrative expenses
|
|
2,156
|
|
|
2,472
|
|
|
(316
|
)
|
|||
Total costs and expenses
|
|
$
|
6,591
|
|
|
$
|
7,346
|
|
|
$
|
(755
|
)
|
|
|
Three Months Ended
September 30,
|
|
|
||||||||
|
|
2015
|
|
2014
|
|
Change
|
||||||
Interest income, net
|
|
$
|
1
|
|
|
$
|
4
|
|
|
$
|
(3
|
)
|
Other income (expense), net
|
|
33
|
|
|
2
|
|
|
31
|
|
|||
Total other income (expense), net
|
|
$
|
34
|
|
|
$
|
6
|
|
|
$
|
28
|
|
|
|
Nine Months Ended September 30,
|
|
|
||||||||
|
|
2015
|
|
2014
|
|
Change
|
||||||
Product revenue
|
|
$
|
394
|
|
|
$
|
428
|
|
|
$
|
(34
|
)
|
Grant revenue
|
|
1,249
|
|
|
1,301
|
|
|
(52
|
)
|
|||
License fee and royalty revenue
|
|
455
|
|
|
215
|
|
|
240
|
|
|||
Total revenue
|
|
$
|
2,098
|
|
|
$
|
1,944
|
|
|
$
|
154
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
September 30,
|
|
|
||||||||
|
|
2015
|
|
2014
|
|
Change
|
||||||
Cost of product revenue
|
|
$
|
521
|
|
|
$
|
1,372
|
|
|
$
|
(851
|
)
|
Research and development expenses
|
|
12,332
|
|
|
13,280
|
|
|
(948
|
)
|
|||
Selling, general, and administrative expenses
|
|
7,086
|
|
|
8,269
|
|
|
(1,183
|
)
|
|||
Total costs and expenses
|
|
$
|
19,939
|
|
|
$
|
22,921
|
|
|
$
|
(2,982
|
)
|
|
|
Nine Months Ended
September 30,
|
|
|
||||||||
|
|
2015
|
|
2014
|
|
Change
|
||||||
Interest income, net
|
|
$
|
3
|
|
|
$
|
6
|
|
|
$
|
(3
|
)
|
Other income (expense), net
|
|
74
|
|
|
10
|
|
|
64
|
|
|||
Total other income (expense), net
|
|
$
|
77
|
|
|
$
|
16
|
|
|
$
|
61
|
|
|
|
Payments Due by Period
|
||||||||||||||||||
|
|
Total
|
|
Less than
1 year
|
|
2-3
years
|
|
4-5
years
|
|
More than
5 years
|
||||||||||
Operating lease obligations
|
|
$
|
6,798
|
|
|
$
|
1,410
|
|
|
$
|
2,925
|
|
|
$
|
2,463
|
|
|
$
|
—
|
|
•
|
public acceptance of such products;
|
•
|
our ability to produce products of consistent quality that offer functionality comparable or superior to existing or new polymer products;
|
•
|
our ability to produce products fit for their intended purpose;
|
•
|
our ability to obtain necessary regulatory approvals for our products;
|
•
|
the speed at which potential customers qualify our biopolymers for use in their products;
|
•
|
the pricing of our products compared to competitive products, including petroleum-based plastics;
|
•
|
the strategic reaction of companies that market competitive products;
|
•
|
our reliance on third parties who support or control production or distribution channels; and
|
•
|
general market conditions.
|
•
|
obtain capital, equipment and facilities,
|
•
|
obtain funding for research and development programs, product development programs and commercialization activities,
|
•
|
obtain expertise in relevant markets,
|
•
|
obtain access to raw materials, and/or
|
•
|
obtain sales and marketing services or support.
|
•
|
our traits may not be successfully validated in the target crops;
|
•
|
our traits may not have the desired effect sought by future collaborators for the relevant crops;
|
•
|
development and validation of traits, particularly during field trials, may be adversely affected by environmental or other circumstances beyond our control;
|
•
|
we or our future collaborators may be unable to obtain the requisite regulatory approvals for the seeds containing our traits;
|
•
|
competitors may launch competing or more effective seed traits or seeds;
|
•
|
a market may not exist for seeds containing our traits or such seeds may not be commercially successful;
|
•
|
future collaborators may be unable to fully develop and commercialize products containing our seed traits or may decide, for whatever reason, not to commercialize such products; and
|
•
|
we may be unable to patent our traits in the necessary jurisdictions.
|
•
|
reported progress in our biopolymers business or with respect to our efforts to spin out Yield10 Bioscience or develop crop related technologies, relative to investor expectations;
|
•
|
changes in earnings estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ earnings estimates;
|
•
|
quarterly variations in our or our competitors’ results of operations;
|
•
|
general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;
|
•
|
future issuances and/or sales of our common stock or preferred stock;
|
•
|
announcements or the absence of announcements by us, or our competitors, regarding acquisitions, new products, significant contracts, commercial relationships or capital commitments;
|
•
|
commencement of, or involvement in, litigation;
|
•
|
any major change in our board of directors or management;
|
•
|
changes in governmental regulations or in the status of our regulatory approvals;
|
•
|
announcements related to patents issued to us or our competitors and to litigation involving our intellectual property;
|
•
|
a lack of, or limited, or negative industry or security analyst coverage;
|
•
|
developments in our industry and general economic conditions;
|
•
|
short-selling or similar activities by third parties; and
|
•
|
other factors described elsewhere in these “Risk Factors.”
|
3.1
|
|
Amended and Restated Certificate of Incorporation (filed herewith).
|
|
|
|
31.1
|
|
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Principal Executive Officer (filed herewith).
|
|
|
|
31.2
|
|
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Principal Financial Officer (filed herewith).
|
|
|
|
32.1
|
|
Section 1350 Certification (furnished herewith).
|
|
|
|
101.1
|
|
The following financial information from the Metabolix Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 formatted in XBRL: (i) Consolidated Balance Sheets, September 30, 2015 and December 31, 2014; (ii) Consolidated Statements of Operations, Three and Nine Months Ended September 30, 2015 and 2014; (iii) Consolidated Statements of Comprehensive Loss, Three and Nine Months Ended September 30, 2015 and 2014; (iv) Consolidated Statements of Cash Flows, Nine Months Ended September 30, 2015 and 2014; and (v) Notes to Consolidated Financial Statements.
|
|
METABOLIX, INC.
|
|
|
|
|
|
|
|
November 12, 2015
|
By:
|
/s/ JOSEPH SHAULSON
|
|
|
Joseph Shaulson
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
November 12, 2015
|
By:
|
/s/ CHARLES B. HAASER
|
|
|
Charles B. Haaser
|
|
|
Chief Accounting Officer
|
|
|
(Principal Financial and Accounting Officer)
|
_
/s/ Joseph Shaulson
_______________________
Joseph Shaulson
President
|
_
/s/ Sarah P. Cecil
_______________________
Sarah P. Cecil
Secretary
|